New hope for tough cancers: first human trial of experimental drug begins
NCT ID NCT06533332
Summary
This is the first human study of an experimental drug called ERX-315 for people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and understand how the body processes the drug. Researchers will also look for early signs that the drug might help control cancer growth in patients with advanced breast, ovarian, pancreatic, and other cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icon Cancer Centre Adelaide
RECRUITINGAdelaide, South Australia, 5037, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Macquarie University Health
RECRUITINGRyde, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Kinghorn Cancer Center
RECRUITINGSydney, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.